Bitcoin price today: surges to $122k, near record high on US regulatory cheer
Christopher M. Starr, a director at Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025. The company’s stock has shown remarkable performance, with a 1,057% return over the past year, according to InvestingPro data. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, for a total value of $672020.
On the same day, Starr also exercised stock options to acquire 16,800 shares of Monopar Therapeutics common stock for a total of $84, with the price of $0.005.
Following these transactions, Starr directly owns 5,173 shares of Monopar Therapeutics, representing a stake in the $249.13 million market cap company. Starr also indirectly owns 9,880 shares held by the Christopher M. Starr and Sheri L. Starr Revocable Trust, for which Dr. Starr serves as Trustee.
In other recent news, Monopar Therapeutics has been initiated with a buy rating by Chardan Capital Markets, highlighting potential in its Wilson disease treatment and radiopharmaceutical pipeline. Chardan set a $60 price target, noting the promising results of ALXN1840, a drug designed to remove copper from the body, which showed significant efficacy in phase III trials. Despite AstraZeneca (NASDAQ:AZN) previously halting the drug’s development, Monopar plans to seek FDA approval in early 2026. Additionally, Monopar will be added to the Russell 3000 and 2000 indexes, a move that acknowledges the company’s growth and development prospects. The inclusion follows the annual reconstitution of the Russell U.S. Indexes, which are used by investment managers to benchmark investment strategies. Monopar’s Chief Financial Officer, Quan Vu, expressed pride in joining the indexes, attributing the achievement to the potential of their drug candidates. The company continues to focus on developing radiopharmaceuticals for cancer treatment, leveraging monoclonal antibodies. Monopar is also actively involved in raising funds to support its clinical and regulatory activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.